Repatha, a PCSK9 inhibitor, lowers cholesterol well, especially for those intolerant to statins, but its absolute risk ...

I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My doctor has put ...

I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My ...

Good afternoon, everyone, and welcome to our first quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Unfavorable lipid profiles are becoming a larger concern in primary care. A noted increase in dyslipidemia among children and ...

Amgen AMGN reported first-quarter adjusted earnings of $5.15 per share, which beat the Zacks Consensus Estimate of $4.73 per ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...

Amgen beat Wall Street expectations in Q1 2026 with $8.62 billion in revenue and $5.15 EPS, driven by strong growth in key drugs like Repatha and Evenity. Management raised full-year revenue and EPS ...